Gujarat Themis Biosyn will host a conference call on August 10, 2026, to discuss its financial performance for the first quarter of fiscal year 2027 (1QFY27). The virtual meeting is scheduled for 14:30 IST and aims to provide stakeholders with insights into the company's recent operational and financial results.

Earnings Call Details

The conference call follows the board meeting held on August 7, which was convened to review the Q1 results. This investor interaction serves as a platform for management to address queries from analysts and institutional investors regarding the quarter's performance. The event is organized in compliance with Regulation 30 and Regulation 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Participation

Senior leadership from Gujarat Themis Biosyn will participate in the discussion to provide clarity on strategic initiatives and financial outcomes. The key representatives attending the call include:

• Dr. Sachin Patel, Managing Director
• Mr. Rajneesh Anand, Non-executive Director
• Mr. Krupesh Patel, Chief Financial Officer

The conference call is being facilitated by 360 ONE CM Research, which will manage the logistics and participant registration. Investors can access the meeting via a dedicated virtual link or through dial-in numbers provided for domestic and international participants.

Access Information

Participants are required to register using the Diamond Pass link provided by the research agency. For those preferring audio access, universal dial-in numbers are available for India, while toll-free options are listed for various international markets including the USA, UK, Australia, and others. The company has ensured broad accessibility to facilitate engagement with its global investor base.

Gujarat Themis Biosyn will convene an Extraordinary General Meeting (EGM) on Saturday, August 22, 2026, to secure shareholder approval for significant related party transactions. The company proposes borrowing up to ₹450 crore and obtaining guarantees worth up to ₹1,000 crore from promoter group entities to fund strategic acquisitions, subsidiary investments, and working capital augmentation. This move provides the company with financial flexibility to execute its growth strategy without sole reliance on external financing.

The proposed transactions involve Dr. Sachin D. Patel, Managing Director and Promoter, along with Pharmaceutical Business Group India Limited (PBGIL) and Themis Medicare Limited (TML). Under the Companies Act, 2013, and SEBI Listing Regulations, these transactions qualify as material related party transactions due to their scale relative to the company’s turnover. The Audit Committee and the Board of Directors have reviewed and approved the terms, which include commercially reasonable interest rates benchmarked against prevailing market rates for similar borrowings. The borrowings are unsecured, though security may be mutually agreed upon.

Key Transaction Details

In addition to the funding approvals, shareholders will vote on a special resolution to amend Article 13(1)(c) of the Articles of Association. The amendment removes the mandatory requirement for a registered valuer’s report for all further issues of share capital, aligning the company’s internal governance with the current statutory framework under the Companies Act, 2013 and SEBI regulations. This change aims to streamline future equity issuances where valuation reports are not legally mandated.

Debt Securities Authorization

The EGM will also consider a special resolution authorizing the private placement of Non-Convertible Debentures (NCDs) and other debt securities. The Board seeks an enabling resolution to issue debt instruments with an outstanding principal amount not exceeding ₹1,500 crore. This authorization allows the company to diversify its debt portfolio and access competitive borrowing sources through private placements to eligible investors, including mutual funds, banks, and institutional buyers. The Board retains discretion to determine terms, pricing, and listing arrangements based on prevailing market conditions.

What the Numbers Show

The scale of the proposed related party transactions is significant relative to the company’s recent financial performance. The proposed borrowing of ₹450 crore represents approximately 271% of the listed entity’s annual standalone turnover for the preceding financial year. Similarly, the proposed guarantee of ₹1,000 crore equates to 603% of that turnover. For context, PBGIL reported a standalone turnover of ₹2.57 crore in FY25, while TML reported ₹342.24 crore. The heavy reliance on promoter group funding underscores the company’s aggressive expansion phase, particularly in strategic acquisitions, which may not yet be fully supported by internal cash flows or traditional banking channels. Shareholders should note that existing borrowings from these entities were nil in FY25, indicating this is a new line of credit rather than a renewal.

Voting and Logistics

Remote e-voting will be available from August 19, 2026, at 9:00 am to August 21, 2026, at 5:00 pm, via the Central Depository Services Limited (CDSL) platform. The cut-off date for voting eligibility is Saturday, August 15, 2026. Shareholders holding shares as on this date can cast their votes electronically. Physical attendance is also permitted at the Vapi venue for those who have not voted remotely. The scrutinizer for the process is Mr. Ketan R. Shirwadkar of M/s. KRS AND CO., Practicing Company Secretaries.